HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-02-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000325 |
| _version_ | 1797281109703131136 |
|---|---|
| author | Wendy B.C. Stevens Katerina Bakunina Marloes Cuijpers Martine Chamuleau Aart Beeker Rob Fijnheer Holger Hebart Hein P.J. Visser Jeanette K. Doorduijn Kim Linton Martin Dreyling Daphne de Jong Marie José Kersten |
| author_facet | Wendy B.C. Stevens Katerina Bakunina Marloes Cuijpers Martine Chamuleau Aart Beeker Rob Fijnheer Holger Hebart Hein P.J. Visser Jeanette K. Doorduijn Kim Linton Martin Dreyling Daphne de Jong Marie José Kersten |
| author_sort | Wendy B.C. Stevens |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:51:46Z |
| format | Article |
| id | doaj.art-23ca07bf9b364b99a59d448aead35389 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:51:46Z |
| publishDate | 2020-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-23ca07bf9b364b99a59d448aead353892024-03-03T04:55:52ZengWileyHemaSphere2572-92412020-02-0141e32510.1097/HS9.0000000000000325202002000-00016HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular LymphomaWendy B.C. StevensKaterina BakuninaMarloes CuijpersMartine ChamuleauAart BeekerRob FijnheerHolger HebartHein P.J. VisserJeanette K. DoorduijnKim LintonMartin DreylingDaphne de JongMarie José Kerstenhttp://journals.lww.com/10.1097/HS9.0000000000000325 |
| spellingShingle | Wendy B.C. Stevens Katerina Bakunina Marloes Cuijpers Martine Chamuleau Aart Beeker Rob Fijnheer Holger Hebart Hein P.J. Visser Jeanette K. Doorduijn Kim Linton Martin Dreyling Daphne de Jong Marie José Kersten HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma HemaSphere |
| title | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title_full | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title_fullStr | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title_full_unstemmed | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title_short | HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma |
| title_sort | hovon110 rebel study results of the phase i part of a randomized phase i ii study of lenalidomide rituximab with or without bendamustine in patients with relapsed refractory follicular lymphoma |
| url | http://journals.lww.com/10.1097/HS9.0000000000000325 |
| work_keys_str_mv | AT wendybcstevens hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT katerinabakunina hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT marloescuijpers hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT martinechamuleau hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT aartbeeker hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT robfijnheer hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT holgerhebart hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT heinpjvisser hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT jeanettekdoorduijn hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT kimlinton hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT martindreyling hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT daphnedejong hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma AT mariejosekersten hovon110rebelstudyresultsofthephaseipartofarandomizedphaseiiistudyoflenalidomiderituximabwithorwithoutbendamustineinpatientswithrelapsedrefractoryfollicularlymphoma |